No Data
Tus-Pharmaceutical Group Co., Ltd.'s (SZSE:000590) Shares Climb 37% But Its Business Is Yet to Catch Up
Enlightenment Pharmaceutical: Report for the third quarter of 2024
tus-pharmaceutical group (000590.SZ): a net loss of 28.4545 million yuan in the first three quarters.
On October 29, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.216 billion yuan in the first three quarters, a year-on-year decrease of 21.26%; the net income attributable to shareholders of the listed company was -28.4545 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -31.8838 million yuan; basic earnings per share was -0.1188 yuan.
Tus-pharmaceutical group (000590.SZ): guangdong Xiantong Pharma currently has no products for the treatment of dengue fever.
According to the investor interaction platform, tus-pharmaceutical group (000590.SZ) stated that its wholly-owned subsidiary, Guangdong Xiantong Pharmaceutical Co., Ltd. currently has no products for the treatment of dengue fever.
Tus-pharmaceutical group (000590.SZ): Received a notice of termination of equity transfer from Ming Shi Pharmaceutical shareholder.
On September 4th, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) announced that on September 3rd, 2024, the company received a notification letter from Wuhan Minshi Pharmaceutical Co., Ltd. (hereinafter referred to as 'Minshi Pharmaceutical') stakeholders Tan Yunliang and Wang Zhong (hereinafter referred to as 'transferor'): due to reasons of the transferor, the transferor has decided to unilaterally terminate the cooperation with the company, terminate the 'Share Transfer Agreement' signed by both parties on February 28th, 2024, and promise to refund the transfer payment received from the company within 7 working days from the date of this notice. In view of the transferor's request to terminate the agreement due to unforeseen reasons, received...
Enlighten Pharmaceutical: 2024 Semi-Annual Report Summary
No Data
No Data